treprostinil
(IQKAWAUTOKVMLE-ZSESPEEFSA-M)
Structure
- SMILES
- CCCCC[C@@H](CC[C@H]1[C@H](O)C[C@H]2[C@@H]1Cc1cccc(c1C2)OCC(=O)[O-])O.[Na+]
- Molecular Formula:
- C23H33NaO5
- Molecular Weight:
- 412.495
- Log P:
- 2.2485
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 2
- TPSA:
- 89.82
- CAS Number(s):
- 289480-64-4
Synonym(s)
1.
treprostinil
2.
((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
3.
Orenitram
4.
Remodulin
5.
UT-15
6.
UT-15C
7.
trepostinil sodium
8.
treprostinil diethanolamine
9.
treprostinil diolamin
10.
treprostinil diolamine
11.
treprostinil sodium
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Pneumonia | FAERS: 3 Canada Vigilance: 11 | Canada Vigilance US FAERS | |
| 2 | Malaise | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 3 | Asthenia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Cataract operation | FAERS: 1 | US FAERS | |
| 5 | Chest Pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 6 | Chest discomfort | FAERS: 1 | US FAERS | |
| 7 | Cyanosis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 8 | Dizziness | FAERS: 1 | US FAERS | |
| 9 | Facial Pain | FAERS: 1 | US FAERS | |
| 10 | Feeling Cold | FAERS: 1 | US FAERS | |
| 11 | Gastrointestinal viral infection | FAERS: 1 | US FAERS | |
| 12 | Hypotension | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 13 | Myocardial necrosis marker increased | FAERS: 1 | US FAERS | |
| 14 | Nausea | FAERS: 1 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 15 | Post procedural complication | FAERS: 1 | US FAERS | |
| 16 | Productive Cough | FAERS: 1 | US FAERS | |
| 17 | Sepsis | FAERS: 1 | US FAERS | |
| 18 | Thrombosis | FAERS: 1 | US FAERS | |
| 19 | White blood cell count decreased | FAERS: 1 | US FAERS | |
| 20 | Abdominal Pain | Canada Vigilance: 1 | Canada Vigilance | |
| 21 | Back Pain | Canada Vigilance: 2 | Canada Vigilance | |
| 22 | Blood creatinine increased | Canada Vigilance: 1 | Canada Vigilance | |
| 23 | Blood potassium decreased | Canada Vigilance: 2 | Canada Vigilance | |
| 24 | Cardiac Arrest | Canada Vigilance: 2 | Canada Vigilance | |
| 25 | Cerebrovascular accident | Canada Vigilance: 1 | Canada Vigilance | |
| 26 | Chills | Canada Vigilance: 1 | Canada Vigilance | |
| 27 | Constipation | Canada Vigilance: 1 | Canada Vigilance | |
| 28 | Dehydration | Canada Vigilance: 1 | Canada Vigilance | |
| 29 | Delirium | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Device breakage | Canada Vigilance: 1 | Canada Vigilance | |
| 31 | Device dislocation | Canada Vigilance: 1 | Canada Vigilance | |
| 32 | Device occlusion | Canada Vigilance: 1 | Canada Vigilance | |
| 33 | Device related sepsis | Canada Vigilance: 1 | Canada Vigilance | |
| 34 | Device use error | Canada Vigilance: 2 | Canada Vigilance | |
| 35 | Disease Progression | Canada Vigilance: 1 | Canada Vigilance | |
| 36 | Drug ineffective | Canada Vigilance: 3 | Canada Vigilance | |
| 37 | Epistaxis | Canada Vigilance: 1 | Canada Vigilance | |
| 38 | Fatigue | Canada Vigilance: 4 | Canada Vigilance | |
| 39 | Feeling abnormal | Canada Vigilance: 2 | Canada Vigilance | |
| 40 | Fluid imbalance | Canada Vigilance: 1 | Canada Vigilance | |
| 41 | Headache | Canada Vigilance: 2 | Canada Vigilance | |
| 42 | Hepatomegaly | Canada Vigilance: 1 | Canada Vigilance | |
| 43 | Hypoxia | Canada Vigilance: 1 | Canada Vigilance | |
| 44 | Incorrect dose administered | Canada Vigilance: 1 | Canada Vigilance | |
| 45 | Infection | Canada Vigilance: 1 | Canada Vigilance | |
| 46 | Infusion Site Extravasation | Canada Vigilance: 2 | Canada Vigilance | |
| 47 | Infusion site abscess | Canada Vigilance: 1 | Canada Vigilance | |
| 48 | Infusion site cellulitis | Canada Vigilance: 1 | Canada Vigilance | |
| 49 | Infusion site discharge | Canada Vigilance: 3 | Canada Vigilance | |
| 50 | Infusion site discomfort | Canada Vigilance: 1 | Canada Vigilance | |
| 51 | Infusion site erosion | Canada Vigilance: 1 | Canada Vigilance | |
| 52 | Infusion site erythema | Canada Vigilance: 2 | Canada Vigilance | |
| 53 | Infusion site infection | Canada Vigilance: 3 | Canada Vigilance | |
| 54 | Infusion site injury | Canada Vigilance: 1 | Canada Vigilance | |
| 55 | Infusion site pain | Canada Vigilance: 8 | Canada Vigilance | |
| 56 | Infusion site pustule | Canada Vigilance: 1 | Canada Vigilance | |
| 57 | Infusion site rash | Canada Vigilance: 1 | Canada Vigilance | |
| 58 | Infusion site swelling | Canada Vigilance: 2 | Canada Vigilance | |
| 59 | Myocardial Infarction | Canada Vigilance: 2 | Canada Vigilance | |
| 60 | N-terminal prohormone brain natriuretic peptide increased | Canada Vigilance: 1 | Canada Vigilance | |
| 61 | Oxygen consumption increased | Canada Vigilance: 2 | Canada Vigilance | |
| 62 | Palpitations | Canada Vigilance: 2 | Canada Vigilance | |
| 63 | Pericardial effusion | Canada Vigilance: 2 | Canada Vigilance | |
| 64 | Peripheral swelling | Canada Vigilance: 3 | Canada Vigilance | |
| 65 | Pneumococcal sepsis | Canada Vigilance: 1 | Canada Vigilance | |
| 66 | Presyncope | Canada Vigilance: 1 | Canada Vigilance | |
| 67 | Product dose omission | Canada Vigilance: 3 | Canada Vigilance | |
| 68 | Pulmonary Embolism | Canada Vigilance: 1 | Canada Vigilance | |
| 69 | Pulmonary Hypertension | Canada Vigilance: 2 | Canada Vigilance | |
| 70 | Respiratory Failure | Canada Vigilance: 1 | Canada Vigilance | |
| 71 | Respiratory tract infection viral | Canada Vigilance: 1 | Canada Vigilance | |
| 72 | Swelling | Canada Vigilance: 1 | Canada Vigilance | |
| 73 | Syncope | Canada Vigilance: 1 | Canada Vigilance | |
| 74 | Vascular device infection | Canada Vigilance: 2 | Canada Vigilance | |
| 75 | Visual Impairment | Canada Vigilance: 1 | Canada Vigilance | |
| 76 | Vomiting | Canada Vigilance: 7 | Canada Vigilance | |
| 77 | Walking distance test abnormal | Canada Vigilance: 2 | Canada Vigilance | |
| 78 | Weight decreased | Canada Vigilance: 3 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.